INDIVIOR PLC(INDV)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

INDV INDIVIOR PLC

盘前交易 10-01 08:13:12 EDT

35.85

-0.74

-2.02%

盘前34.55

-1.30-3.63%

07:14 EDT

最高36.60	最低35.79	成交量167.36万
今开36.54	昨收36.59	日振幅2.21%
总市值42.30亿	流通市值41.75亿	总股本1.18亿
成交额6,028万	换手率1.44%	流通股本1.16亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"INDV","market":"US","secType":"STK","nameCN":"INDIVIOR PLC","latestPrice":35.85,"timestamp":1790798400000,"preClose":36.59,"halted":0,"volume":1673557,"hourTrading":{"tag":"盘前","latestPrice":34.55,"preClose":35.85,"latestTime":"07:14 EDT","volume":3,"amount":104.840001,"timestamp":1790853256666,"change":-1.3,"changeRate":-0.036262,"amplitude":0.033194},"delay":0,"changeRate":-0.020224104946706803,"floatShares":116454522,"shares":118000000,"eps":2.766067,"marketStatus":"盘前交易","change":-0.74,"latestTime":"10-01 08:13:12 EDT","open":36.54,"high":36.6,"low":35.79,"amount":60275108.396019004,"amplitude":0.022137,"askPrice":36.87,"askSize":62,"bidPrice":35.01,"bidSize":62,"shortable":3,"etf":0,"ttmEps":2.766067,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790861400000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":35.85,"preHourTrading":{"tag":"盘前","latestPrice":34.55,"preClose":35.85,"latestTime":"07:14 EDT","volume":3,"amount":104.840001,"timestamp":1790853256666,"change":-1.3,"changeRate":-0.036262,"amplitude":0.033194},"postHourTrading":{"tag":"盘后","latestPrice":35.85,"preClose":35.85,"latestTime":"19:55 EDT","volume":221467,"amount":7939557.6616,"timestamp":1790812505265,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.1072887505365716,"impliedVol":0.3876,"impliedVolPercentile":0.264},"requestUrl":"/m/hq/s/INDV","defaultTab":"news","newsList":[{"id":"1163108633","title":"Indivior制药特别股息派发取决于Supernus并购完成，预计2026年11月2日落地","url":"https://stock-news.laohu8.com/highlight/detail?id=1163108633","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163108633?lang=zh_cn&edition=full","pubTime":"2026-09-17 19:20","pubTimestamp":1789644043,"startTime":"0","endTime":"0","summary":"Indivior制药宣布，其特别股息支付将以Supernus并购交易的正式完成为前提条件。目前从市场预期来看，这一并购的收尾节点有望落在2026年11月2日。\n据悉，此次特别股息的发放并非无条件的既定安排，而是与并购交割深度绑定——只有在Supernus交易顺利闭环之后，股东才有资格获得这笔现金回报。换言之，交易一旦出现延误或变数，股息时间表也将随之调整。\n对投资者而言，这一消息意味着两重关注点交织：一方面，并购本身带来的业务整合与协同效应值得密切追踪；另一方面，股息兑现的时点则为持有者提供了一个相对明确的观察窗口。市场目光正聚焦于2026年11月2日这一关键日期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","INDV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163070222","title":"Indivior制药加速终止合作包装供应协议，生效日提前至2027年1月15日——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1163070222","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163070222?lang=zh_cn&edition=full","pubTime":"2026-09-16 04:32","pubTimestamp":1789504331,"startTime":"0","endTime":"0","summary":"Indivior制药公司近日向美国证券交易委员会提交的文件显示，其与合作包装商的供应协议终止日期已被提前至2027年1月15日。据悉，Indivior制药与相关合作包装商之间的供应协议，涉及特定产品的包装环节。值得注意的是，这一变更信息通过官方SEC文件正式对外公布，凸显了公司在优化运营结构方面的最新举措。截至目前，Indivior制药尚未就协议加速终止的具体原因、对生产流程的潜在影响以及后续替代方案等细节作出进一步公开说明。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INDV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145265589","title":"Indivior制药：Indivior UK Limited与利洁时签署变更契据及终止协议——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1145265589","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145265589?lang=zh_cn&edition=full","pubTime":"2026-09-16 04:32","pubTimestamp":1789504329,"startTime":"0","endTime":"0","summary":"Indivior制药（INDIVIOR PLC）——该公司旗下Indivior UK Limited已与利洁时（Reckitt Benckiser）达成一项变更契据及终止协议，相关细节已通过美国证券交易委员会（SEC）文件正式对外披露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INDV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171272899","title":"Indivior制药锁定新供应商 验证后义务即刻生效——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1171272899","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171272899?lang=zh_cn&edition=full","pubTime":"2026-09-16 04:32","pubTimestamp":1789504329,"startTime":"0","endTime":"0","summary":"Indivior制药已敲定一家全新供应商，并明确相关义务将在验证流程完成后正式具备执行力。这一消息源自公司向美国证券交易委员会提交的最新文件。分析人士指出，此举反映出Indivior在供应链管理上的审慎态度，尤其是在当前全球医药产业链波动加剧的背景之下，提前锁定备选来源、设置清晰的生效节点，不失为一种风险缓释的务实之举。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","INDV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126138791","title":"INDIVIOR PLC：特定情况下若终止合并协议，Supernus须支付1.01亿美元解约费","url":"https://stock-news.laohu8.com/highlight/detail?id=1126138791","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126138791?lang=zh_cn&edition=full","pubTime":"2026-08-03 18:43","pubTimestamp":1785753788,"startTime":"0","endTime":"0","summary":"INDIVIOR PLC披露了一项关键条款：在特定条件下，倘若合并协议被终止，Supernus公司将必须向该公司支付高达1.01亿美元的终止费用。这一巨额解约费安排，为潜在并购交易增添了新的博弈维度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INDV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126840600","title":"Supernus：合并后公司将立即获得规模优势，并预计实现1.25亿美元年度成本协同效应","url":"https://stock-news.laohu8.com/highlight/detail?id=1126840600","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126840600?lang=zh_cn&edition=full","pubTime":"2026-08-03 18:35","pubTimestamp":1785753308,"startTime":"0","endTime":"0","summary":"Supernus Pharmaceuticals 表示，合并后的实体预计将立即受益于规模效应。与此同时，该公司还预期每年可实现高达1.25亿美元的成本协同效应。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INDV","BK4007","SUPN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131807040","title":"Supernus：Indivior Pharmaceuticals 股东将在合并交割前一次性获得总计10亿美元的特别现金股息","url":"https://stock-news.laohu8.com/highlight/detail?id=1131807040","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131807040?lang=zh_cn&edition=full","pubTime":"2026-08-03 18:33","pubTimestamp":1785753239,"startTime":"0","endTime":"0","summary":"Supernus Pharmaceuticals 宣布，Indivior Pharmaceuticals 的股东们将在合并交易正式完成之前，立即获得一笔总额高达10亿美元的一次性特别现金股息。这笔款项将以现金形式发放，旨在合并程序启动前向股东兑现价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INDV","BK4007","SUPN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146904506","title":"Supernus Pharmaceuticals股东将按每股获得1.5401股Indivior Pharmaceuticals普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1146904506","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146904506?lang=zh_cn&edition=full","pubTime":"2026-08-03 18:32","pubTimestamp":1785753134,"startTime":"0","endTime":"0","summary":"Supernus Pharmaceuticals（SUPN）的股东，即将迎来一项重大资产转换。根据最新披露的信息，他们手中持有的每一股Supernus Pharmaceuticals股份，将对应换取1.5401股Indivior Pharmaceuticals（INDV）的普通股。这一兑换比例，清晰地勾勒出两家公司间交易结构的核心轮廓。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INDV","BK4007","SUPN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115687529","title":"Supernus Pharmaceuticals：Indivior 股东将持有合并后公司约56.5%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1115687529","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115687529?lang=zh_cn&edition=full","pubTime":"2026-08-03 18:32","pubTimestamp":1785753134,"startTime":"0","endTime":"0","summary":"Supernus Pharmaceuticals公布，与Indivior的合并交易完成后，Indivior股东将持有合并后实体约56.5%的股份。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SUPN","INDV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137788348","title":"Supernus Pharmaceuticals Inc合并后实体将更名为Supernus, Inc.，Jack Khattar出任总裁兼CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=1137788348","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137788348?lang=zh_cn&edition=full","pubTime":"2026-08-03 18:31","pubTimestamp":1785753069,"startTime":"0","endTime":"0","summary":"Supernus Pharmaceuticals Inc宣布，其合并后的实体将正式命名为Supernus, Inc.。与此同时，Jack Khattar将担任该公司的总裁兼首席执行官。这一举措标志着公司整合进程中的关键一步，为未来的发展战略奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INDV","SUPN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166873281","title":"巴克莱银行首次覆盖INDIVIOR PLC，给予“增持”评级及46美元目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1166873281","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166873281?lang=zh_cn&edition=full","pubTime":"2026-06-18 18:35","pubTimestamp":1781778955,"startTime":"0","endTime":"0","summary":"巴克莱银行近日启动对INDIVIOR PLC的研究覆盖，并给予该股“增持”评级，同时设定46美元的目标股价。此举标志着这家知名金融机构对INDIVIOR PLC未来前景的积极看法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INDV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148881603","title":"INDIVIOR PLC将于2026年6月1日起取消首席科学官职位——根据SEC文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1148881603","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148881603?lang=zh_cn&edition=full","pubTime":"2026-05-16 04:05","pubTimestamp":1778875514,"startTime":"0","endTime":"0","summary":"根据向美国证券交易委员会（SEC）提交的文件，INDIVIOR PLC决定自2026年6月1日起，正式取消公司内部的首席科学官职位。这一组织结构调整将于指定日期生效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INDV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141939535","title":"Indivior制药Q1营收3.17亿美元 大幅超越IBES预期2.728亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1141939535","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141939535?lang=zh_cn&edition=full","pubTime":"2026-04-30 19:15","pubTimestamp":1777547706,"startTime":"0","endTime":"0","summary":"Indivior制药公布第一季度净利润达8900万美元，业绩表现亮眼。相较于市场预期，公司营收实现显著突破，第一季度营收规模达到3.17亿美元，远超IBES机构预测的2.728亿美元。\n强劲的营收增长凸显了公司核心产品的市场竞争力，同时净利润数据也印证了其高效的运营管理能力。在医药行业面临多重挑战的背景下，这一业绩无疑为投资者注入了信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INDV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518227836","title":"Indivior Plc盘中异动 股价大跌5.05%报9.21美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518227836","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518227836?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:00","pubTimestamp":1741615234,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时00分，Indivior Plc股票出现波动，股价大幅下跌5.05%。截至发稿，该股报9.21美元/股，成交量10.7675万股，换手率0.09%，振幅1.70%。Indivior Plc股票所在的制药行业中，整体跌幅为1.61%。其相关个股中，Sonoma Pharmaceuticals, Inc.、Sunshine Biopharma Inc C/Wts 、Medicus Pharma Ltd.涨幅较大，Sonoma Pharmaceuticals, Inc.、Petros Pharmaceuticals, Inc.、苏轩堂较为活跃，换手率分别为338.15%、13.89%、10.15%，振幅较大的相关个股有Scilex Holding Company C/Wts 10/11/2027 、Sonoma Pharmaceuticals, Inc.、苏轩堂，振幅分别为35.91%、31.15%、29.45%。Indivior Plc公司简介：Indivior PLC 是一家专业仿制药生产公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310220035a26a2fdc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310220035a26a2fdc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INDV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517988604","title":"Indivior Plc盘中异动 急速拉升5.24%报10.05美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517988604","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517988604?lang=zh_cn&edition=full","pubTime":"2025-03-05 03:08","pubTimestamp":1741115333,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日03时08分，Indivior Plc股票出现异动，股价大幅上涨5.24%。截至发稿，该股报10.05美元/股，成交量121.105万股，换手率0.97%，振幅9.11%。Indivior Plc股票所在的制药行业中，整体跌幅为0.74%。其相关个股中，Biofrontera Inc C/Wts 27/10/2026 、坎伯兰药业、Esperion Therapeutics, Inc.涨幅较大，Petros Pharmaceuticals, Inc.、大自然药业、Emergent Biosolutions Inc.较为活跃，换手率分别为23.46%、7.90%、7.68%，振幅较大的相关个股有坎伯兰药业、Petros Pharmaceuticals, Inc.、Medicus Pharma Ltd.，振幅分别为30.93%、22.75%、22.63%。Indivior Plc公司简介：Indivior PLC 是一家专业仿制药生产公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305030853abe83bf7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305030853abe83bf7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","PTPI","INDV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516305326","title":"Indivior Plc盘中异动 股价大涨5.03%报9.71美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516305326","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516305326?lang=zh_cn&edition=full","pubTime":"2025-03-03 23:08","pubTimestamp":1741014484,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日23时08分，Indivior Plc股票出现波动，股价急速上涨5.03%。截至发稿，该股报9.71美元/股，成交量52.883万股，换手率0.43%，振幅2.81%。Indivior Plc股票所在的制药行业中，整体涨幅为0.36%。其相关个股中，Sunshine Biopharma Inc C/Wts 、坎伯兰药业、Intercure Ltd.涨幅较大，Petros Pharmaceuticals, Inc.、苏轩堂、大自然药业较为活跃，换手率分别为7.56%、7.32%、4.64%，振幅较大的相关个股有Sunshine Biopharma Inc C/Wts 、Cyclo Therapeutics Inc C/Wts 11/12/2025、Organogenesis Holdings Inc.，振幅分别为30.32%、15.13%、12.08%。Indivior Plc公司简介：Indivior PLC 是一家专业仿制药生产公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032308049637b68a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032308049637b68a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INDV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514207943","title":"Indivior Plc盘中异动 大幅跳水5.41%报8.40美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514207943","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514207943?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:30","pubTimestamp":1740753038,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日22时30分，Indivior Plc股票出现异动，股价大幅跳水5.41%。截至发稿，该股报8.40美元/股，成交量5.1113万股，换手率0.04%，振幅0.00%。Indivior Plc股票所在的制药行业中，整体涨幅为0.00%。其相关个股中，Organogenesis Holdings Inc.、Ani Pharmaceuticals, Inc.、Collegium Pharmaceutical, Inc.涨幅较大，Petros Pharmaceuticals, Inc.、大自然药业、Quantum Biopharma Ltd.较为活跃，换手率分别为1.68%、1.39%、0.59%，振幅较大的相关个股有Kamada Ltd.、Cronos Group Inc. Common Share、Organogenesis Holdings Inc.，振幅分别为3.62%、2.00%、1.57%。Indivior Plc公司简介：Indivior PLC 是一家专业仿制药生产公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228223039abe0e9ca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228223039abe0e9ca&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","INDV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514331085","title":"Indivior Plc盘中异动 下午盘大幅上涨5.01%报9.01美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514331085","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514331085?lang=zh_cn&edition=full","pubTime":"2025-02-28 03:25","pubTimestamp":1740684317,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日03时25分，Indivior Plc股票出现波动，股价快速拉升5.01%。截至发稿，该股报9.01美元/股，成交量166.503万股，换手率1.34%，振幅7.11%。Indivior Plc股票所在的制药行业中，整体跌幅为0.12%。其相关个股中，Medicus Pharma Ltd.、Cronos Group Inc. Common Share、Therapeuticsmd, Inc.涨幅较大，Petros Pharmaceuticals, Inc.、苏轩堂、大自然药业较为活跃，换手率分别为34.16%、15.12%、11.55%，振幅较大的相关个股有Sunshine Biopharma Inc C/Wts 、Biofrontera Inc C/Wts 27/10/2026 、Petros Pharmaceuticals, Inc.，振幅分别为49.11%、43.07%、25.88%。Indivior Plc公司简介：Indivior PLC 是一家专业仿制药生产公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502280325179632e735&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502280325179632e735&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PTPI","INDV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514018051","title":"Indivior Plc盘中异动 急速下挫5.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514018051","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514018051?lang=zh_cn&edition=full","pubTime":"2025-02-25 22:31","pubTimestamp":1740493876,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日22时31分，Indivior Plc股票出现异动，股价大幅下挫5.39%。截至发稿，该股报7.81美元/股，成交量3.4644万股，换手率0.03%，振幅0.24%。Indivior Plc股票所在的制药行业中，整体涨幅为0.85%。其相关个股中，Redhill Biopharma Ltd、Petros Pharmaceuticals, Inc.、Medicus Pharma Ltd.涨幅较大，Redhill Biopharma Ltd、Petros Pharmaceuticals, Inc.、苏轩堂较为活跃，换手率分别为118.35%、61.87%、12.04%，振幅较大的相关个股有Sunshine Biopharma Inc C/Wts 、Petros Pharmaceuticals, Inc.、大自然药业，振幅分别为18.63%、7.66%、6.26%。Indivior Plc公司简介：Indivior PLC 是一家专业仿制药生产公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225223117abdc7dbb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225223117abdc7dbb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INDV","BK4007","PTPI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513756130","title":"Indivior Plc2024财年实现净利润-48.00百万美元，同比减少2500.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513756130","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513756130?lang=zh_cn&edition=full","pubTime":"2025-02-24 00:00","pubTimestamp":1740326425,"startTime":"0","endTime":"0","summary":"2月24日，Indivior Plc公布财报，公告显示公司2024财年净利润为-48.00百万美元，同比减少2500.00%；其中营业收入为11.88亿美元，同比增加8.69%，每股基本收益为-0.36美元。从资产负债表来看，Indivior Plc总负债16.71亿美元，其中短期债务28.00百万美元，资产负债比为0.88，流动比率为0.88。机构评级：截至2025年2月24日，当前有7家机构对Indivior Plc目标价做出预测，其中目标均价为15.45美元，其中最低目标价为13.90美元，最高目标价为16.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224000038abd9c79b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224000038abd9c79b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INDV"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.indivior.com","stockEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":0.0263},{"period":"3month","weight":-0.0992},{"period":"6month","weight":0.1766},{"period":"1year","weight":0.4869},{"period":"ytd","weight":-0.0008}],"compareEarnings":[{"period":"1week","weight":-0.0067},{"period":"1month","weight":-0.0058},{"period":"3month","weight":0.024},{"period":"6month","weight":0.1628},{"period":"1year","weight":0.1448},{"period":"ytd","weight":0.1184}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Indivior Pharmaceuticals, Inc.于2014年9月26日在英格兰和威尔士的法律下注册成立为一家公共有限公司，并于2026年1月26日在特拉华州重新注册。Indivior致力于通过研发治疗阿片类药物使用障碍（OUD）的药物来改善患者的生活。基于其现有的OUD治疗产品组合，Indivior拥有一系列候选产品，旨在进一步拓展其在该领域的业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.583333,"avgChangeRate":0.021864},{"month":2,"riseRate":0.583333,"avgChangeRate":0.011788},{"month":3,"riseRate":0.416667,"avgChangeRate":-0.007447},{"month":4,"riseRate":0.833333,"avgChangeRate":0.037804},{"month":5,"riseRate":0.833333,"avgChangeRate":0.065087},{"month":6,"riseRate":0.5,"avgChangeRate":0.060391},{"month":7,"riseRate":0.727273,"avgChangeRate":0.153964},{"month":8,"riseRate":0.5,"avgChangeRate":-0.023761},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.08526},{"month":10,"riseRate":0.363636,"avgChangeRate":0.007009},{"month":11,"riseRate":0.545455,"avgChangeRate":0.010295},{"month":12,"riseRate":0.636364,"avgChangeRate":0.020229}],"exchange":"NASDAQ","name":"INDIVIOR PLC","nameEN":"INDIVIOR PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"INDIVIOR PLC(INDV)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供INDIVIOR PLC(INDV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"INDIVIOR PLC,INDV,INDIVIOR PLC股票,INDIVIOR PLC股票老虎,INDIVIOR PLC股票老虎国际,INDIVIOR PLC行情,INDIVIOR PLC股票行情,INDIVIOR PLC股价,INDIVIOR PLC股市,INDIVIOR PLC股票价格,INDIVIOR PLC股票交易,INDIVIOR PLC股票购买,INDIVIOR PLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"INDIVIOR PLC(INDV)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供INDIVIOR PLC(INDV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}